Neurobiology of alzheimer’s disease: Integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions

Current Alzheimer Research

Volumn 12, Issue 8, 2015, Pages 712-722

  Raskin, Joel ^a   Cummings, Jeffrey ^b   Hardy, John ^c   Schuh, Kory ^a   Dean, Robert A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer s disease; Anatomical; Biomarker; Cognition; Molecular; Neurobiology; Physiological

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CHOLINE ACETYLTRANSFERASE; GLUCOSE; INSULIN; MICRORNA; PHOSPHATIDYLINOSITOL BINDING CLATHRIN ASSEMBLY PROTEIN; PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BRAIN ATROPHY; BRAIN METABOLISM; CELL LOSS; CEREBROSPINAL FLUID; CLINICAL FEATURE; COGNITION; DEFAULT MODE NETWORK; DENTATE GYRUS; DISEASE COURSE; DYSTROPHY; ENZYME ACTIVITY; GENETIC RISK; GLIA CELL; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; INFLAMMATION; MENTAL DETERIORATION; METABOLIC RATE; NERVE CELL NECROSIS; NERVE CELL NETWORK; NERVE FIBER TRANSPORT; NEUROANATOMY; NEUROBIOLOGY; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYNAPSE; SYNAPTIC TRANSMISSION; COGNITION DISORDERS; COMPLICATION; GENETICS; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; BIOMARKERS; COGNITION DISORDERS; HUMANS; NEUROBIOLOGY;

EID: 84942082866     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150701103107     Document Type: Article

References (97)

1. Alzheimer's Association. 2012 Alzheimer's Disease Facts and Figures. Alzheimers Dement 8(2): 131-68 (2012).
2. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 9(11): 1118-1127 (2010).
3. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12(2): 207-216 (2013).
4. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3): 280-292 (2011).
5. Martins IJ, Berger T, Sharman MJ, Verdile G, Fuller SJ, Martins RN. Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. J Neurochem 111(6): 1275-1308 (2009).
6. Bendlin BB, Carlsson CM, Gleason CE, Johnson SC, Sodhi A, Gallagher CL, et al. Midlife predictors of Alzheimer's disease. Maturitas 65(2): 131-137 (2010).
7. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33, and CD2AP are associated with Alzheimer's disease. Nat Genet 43(5): 429-435 (2011).
8. Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 77(1): 43-51 (2015).
9. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes. Nat Genet 41(10): 1088-1093 (2009).
10. Singaraja RR. TREM2: a new risk factor for Alzheimer's disease. Clin Genet 83(6): 525-526 (2013).
11. Guerreiro R, Wojtas A, Bras J, Gibbs JR, Rohrer JD, Gurunlian N, et al. TREM2 variants in Alzheimer's disease. New Engl J Med 368(2): 117-127 (2013).
12. Bhattacharjee S, Zhao Y, Lukiw WJ. Deficits in the miRNA-34aregulated endogenous TREM2 phagocytosis sensor-receptor in Alzheimer's disease (AD); an update. Front Aging Neurosci 6: 116 (2014).
13. Kong Y, Wu JB, Wang X, Zhao JF, Song H, Yuan LD. Polymorphism of the OLR1 3'UTR potential microRNA binding site and risk of Alzheimer's disease: a meta-analysis. Genet Mol Res 13(4): 10162-72 (2014).
14. Long JM, Ray B, Lahiri DK. MicroRNA-153 physiologically inhibits expression of amyloid-β precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. J Biol Chem 287(37): 31298-310 (2012).
15. Long JM, Ray B, Lahiri DK. MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. J Biol Chem 289(8): 5184-98 (2014).
16. Galimberti D, Villa C, Fenoglio C, Serpente M, Ghezzi L, Cioffi SM, et al. Circulating miRNAs as potential biomarkers in Alzheimer's disease. J Alzheimers Dis 42(4): 1261-7 (2014).
17. Barbash S, Soreq H.Threshold-independent meta-analysis of Alzheimer's disease transcriptomes shows progressive changes in hippocampal functions, epigenetics and microRNA regulation. Curr Alzheimer Res 9(4): 425-35 (2012).
18. Acx H, Chavez Gutierrez L, Serneels L, De Strooper B. The composition of the γ-secretase complex defines its Aβ product profile. Mol Neurodegener 8(1): P2 (2013).
19. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 377(9770): 1019-1031 (2011).
20. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120(4): 545-555 (2005).
21. Jack CR, Jr., Shiung MM, Weigand SD, O'Brien PC, Gunter JL, Boeve BF, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 65(8): 1227-1231 (2005).
22. Jack CR, Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9(1): 119-128 (2010).
23. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8(1): 1-13 (2012).
24. Glenner GG, Wong CW. Alzheimer's disease and Down syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122(3): 1131-1135 (1984).
25. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580): 353-356 (2002).
26. O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci 34: 185-204 (2011).
27. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283(44): 29615-29619 (2008).
28. Bell RD, Zlokovic BV. Neurovascular mechanisms and bloodbrain barrier disorder in Alzheimer's disease. Acta Neuropathol 118(1): 103-113 (2009).
29. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 18(2): 253-266 (2008).
30. Carare RO, Bernardes-Silva, M, Newman, TA, Page, AM, Nicoll, JAR, Perry VH, et al. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol App Neurobiol 34: 131-144 (2008).
31. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8(2): 101-112 (2007).
32. Zhang YW, Thompson R, Zhang H, Xu H. APP processing in Alzheimer's disease. Mol Brain 4: 3 (2011).
33. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330(6012): 1774 (2010).
34. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer's β-amyloid precursor protein depends on lipid rafts. J Cell Biol 160(1): 113-123 (2003).
35. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease.N Engl J Med 369(4): 341-50 (2013).
36. De Strooper B. Lessons from a failed γ -secretase Alzheimer trial. Cell 159(4): 721-6 (2014).
37. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488: 96-99 (2012).
38. Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer's disease. Lancet Neurol 12(1): 92-104 (2013).
39. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370(4): 311-21 (2014).
40. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18(4): 351-357 (1997).
41. Friedrich RP, Tepper K, Ronicke R, Soom M, Westermann M, Reymann K, et al. Mechanism of amyloid plaque formation suggests an intracellular basis of Abeta pathogenicity. Proc Natl Acad Sci USA 107(5): 1942-1947 (2010).
42. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow D. Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci USA 100(1): 330-335 (2003).
43. Ono K, Condron MM, Teplow DB. Structure-neurotoxicity relationships of amyloid β -protein oligomers. Proc Natl Acad Sci 106(35): 14745-14750 (2009).
44. Yu L, Edalji R, Harlan JE, Holzman TF, Lopez AP, Labkovsky B, et al. Structural characterization of a soluble amyloid beta-peptide oligomer. Biochemistry 48(9): 1870-1877 (2009).
45. Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, et al. Biological markers of amyloid β-related mechanisms in Alzheimer's disease. Exp Neurol 223(2): 334-346 (2010).
46. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14(8): 837-842 (2008).
47. Mucke L, Selkoe D. Neurotoxicity of amyloid b-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2(7): a006338 (2012).
48. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2(1): a006346 (2012).
49. Neumann H, Daly MJ. Variant TREM2 as risk factor for Alzheimer's disease. N Engl J Med 368(2): 182-184 (2013).
50. Desikan RS, Schork AJ, Wang Y, Thompson WK, Dehghan A, Ridker PM, et al. Polygenic overlap between C-reactive protein, plasma lipids and Alzheimer's disease. Circulation 131(23): 2061-9 (2015).
51. Steele ML, Robinson SR. Reactive astrocytes give neurons less support: implications for Alzheimer's disease. Neurobiol Aging 33(2): 423.e1-423.e13 (2012).
52. Reddy PH. Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease. Brain Res 1415: 136-148 (2011).
53. Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 14(2): 45-53 (2008).
54. Calkins MJ, Reddy PH. Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons. Biochim Biophys Acta 1812(4): 507-513 (2011).
55. Stohr J, Watts JC, Mensinger ZL, Oehler A, Grillo SK, DeArmond SJ, et al. Purified and synthetic Alzheimer's amyloid beta (Aβ) prions. Proc Natl Acad Sci 109(27): 11025-11030 (2012).
56. Walker L, Diamond MI, Duff KE, Hyman BT. Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol 70(3): 304-310 (2013).
57. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739(2-3): 198-210 (2005).
58. Berriman J, Serpell LC, Oberg KA, Fink AL, Goedert M, Crowther RA. Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci USA 100(15): 9034-9038 (2003).
59. Tapiola T, Overmyer M, Lehtovirta M, Helisalmi S, Ramberg J, Alafuzoff I, et al. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport 8(18): 3961-3963 (1997).
60. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainene P, Soininen H, et al. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66(3): 382-389 (2009).
61. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, et al. Trans-synaptic spread of tau pathology in vivo. PLoS One 7(2): e31302 (2012).
62. Mintun M, Schwarz A, Joshi A, Shcherbinin S, Chien D, Elizarov A, et al. Exploratory analyses of regional human brain distribution of the PET tau tracer F18-labeled T807 (AV-1541) in subjects with normal cognitive function or cognitive impairment thought to be due to Alzheimer's disease. Alzheimers Dement 9(4): P842 (2013).
63. Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 24(8): 1079-1085 (2003).
64. Gotz J, Ittner LM, Kins S. Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? J Neurochem 98(4): 993-1006 (2006).
65. Ittner LM, Gotz J. Amyloid-beta and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12(2): 65-72 (2011).
66. Fein JA, Sokolow S, Miller CA, Vinters HV, Yang F, Cole GM, et al. Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes. Am J Pathol 172(6): 1683-1692 (2008).
67. Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging 36(5): 811-822 (2009).
68. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 159(5): 738-745 (2002).
69. Schwartz WJ, Smith CB, Davidsen L, Savaki H, Sokoloff L, Mata M, et al. Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science 205(4407): 723-725 (1979).
70. Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab 21(10): 1133-1145 (2001).
71. Kadekaro M, Crane AM, Sokoloff L. Differential effects of electrical stimulation of sciatic nerve on metabolic activity in spinal cord and dorsal root ganglion in the rat. Proc Natl Acad Sci USA 82(17): 6010-6013 (1985).
72. Rocher AB, Chapon F, Blaizot X, Baron JC, Chavoix C. Restingstate brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage 20(3): 1894-1898 (2003).
73. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. Eur J Nucl Med Mol Imaging 32(4): 486-510 (2005).
74. Hoyer S, Oesterreich K, Wagner O. Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type? J Neurol 235(3): 143-8 (1988).
75. Hoyer S. The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update.J Neural Transm 109(3): 341-60 (2002).
76. Morgen K, Frolich L. The metabolism hypothesis of Alzheimer's disease: from the concept of central insulin resistance and associated consequences to insulin therapy. J Neural Transm 122(4): 499-504 (2015).
77. Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathol 118(1): 167-179 (2009).
78. Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 27(10): 1372-1384 (2006).
79. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68(18): 1501-1508 (2007).
80. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2(6150): 1457-1459 (1978).
81. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, et al. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neurosci Lett 380(1-2): 127-132 (2005).
82. Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurol 52(4): 691-699 (1999).
83. Alkalay A, Rabinovici GD, Zimmerman G, Agarwal N, Kaufer D, Miller BL, et al. Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load. Curr Alzheimer Res 10(1): 48-56 (2013).
84. Henneman WJ, Sluimer JD, Barnes J, van der Flier WM, Sluimer IC, Fox NC, et al. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 72(11): 999-1007 (2009).
85. Barnes J, Bartlett JW, van de Pol LA, Loy CT, Scahill RI, Frost C, et al. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging 30(11): 1711-1723 (2009).
86. Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol 5(10): 828-834 (2006).
87. Tondelli M, Wilcock GK, Nichelli P, De Jager CA, Jenkinson M, Zamboni G. Structural MRI changes detectable up to ten years before clinical Alzheimer's disease. Neurobiol Aging 33(4): 825.e25-825.e36 (2012).
88. Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloidpositive individuals. Cereb Cortex 19(3): 497-510 (2009).
89. Stebbins GT, Murphy CM. Diffusion tensor imaging in Alzheimer's disease and mild cognitive impairment. Behav Neurol 21(1): 39-49 (2009).
90. Harris JA, Devidze N, Verret L, Ho K, Halabisky B, Thwin MT, et al. Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron 68: 428-441 (2010).
91. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function, and relevance to disease. Ann NY Acad Sci 1124: 1-38 (2008).
92. Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63(2): 178-188 (2009).
93. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA 101(13): 4637-4642 (2004).
94. Wang K, Liang M, Wang L, Tian L, Zhang X, Li K, et al. Altered functional connectivity in early Alzheimer's disease: a resting-state fMRI study. Hum Brain Map 28: 967-78 (2007).
95. Supekar K, Menon V, Rubin D, Musen M, Greicius MD. Network analysis of intrinsic functional brain connectivity in Alzheimer's disease. PLoS Comput Biol 4(6): e1000100 (2008).
96. Zhong Y, Huang L, Cai S, Zhang Y, von Deneen KM, Ren A, et al.Altered effective connectivity patterns of the default mode network in Alzheimer's disease: an fMRI study. Neurosci Lett 578: 171-5 (2014).
97. Mormino EC, Smiljic A, Hayenga AO, Onami SH, Greicius MD, Rabinovici GD, et al. Relationships between beta-amyloid and functional connectivity in different components of the default mode network in aging. Cereb Cortex 21(10): 2399-2407 (2011).